{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:21:15Z","timestamp":1790742075210,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtos.2024.11.008","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:58:27Z","timestamp":1732813107000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Laura E.","family":"Downie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer P.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndon W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bosworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2024.11.008_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland","volume":"52","author":"Knop","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","article-title":"The international workshop on meibomian gland dysfunction: executive summary","volume":"52","author":"Nichols","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib3","doi-asserted-by":"crossref","first-page":"TFOS1","DOI":"10.1167\/iovs.13-13195","article-title":"The TFOS international workshop on contact lens discomfort: introduction","volume":"54","author":"Nichols","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/ICO.0b013e3181d4f366","article-title":"Nonobvious obstructive meibomian gland dysfunction","volume":"29","author":"Blackie","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","article-title":"The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee","volume":"52","author":"Nelson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib6","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1167\/iovs.11-9228","article-title":"Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain","volume":"53","author":"Viso","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","article-title":"Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study","volume":"31","author":"Lemp","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1167\/iovs.10-6997e","article-title":"The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD","volume":"52","author":"Schaumberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib9","first-page":"117","article-title":"Sebum flow dynamics and antidandruff shampoos","volume":"48","author":"Pierard-Franchimont","year":"1997","journal-title":"J Soc Cosmet Chem"},{"key":"10.1016\/j.jtos.2024.11.008_bib10","first-page":"489","article-title":"Increased sebum secretion following selenium sulfide shampoos","volume":"48","author":"Goldschmidt","year":"1968","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2024.11.008_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtos.2023.07.002","article-title":"Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: a vehicle-controlled, randomized clinical trial","volume":"29","author":"Watson","year":"2023","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2024.11.008_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2340\/00015555-2051","article-title":"Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial","volume":"95","author":"\u00c5kerstr\u00f6m","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2024.11.008_bib13","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ICO.0b013e3181814cff","article-title":"Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location","volume":"27","author":"Korb","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2024.11.008_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/ICO.0b013e3181ba0cb2","article-title":"Prevalence of lid wiper epitheliopathy in subjects with dry eye signs and symptoms","volume":"29","author":"Korb","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib16","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/ICO.0b013e318239aaea","article-title":"A new system, the LipiFlow, for the treatment of meibomian gland dysfunction","volume":"31","author":"Lane","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archopht.1973.01000040105007","article-title":"Factors affecting tear film breakup in normal eyes","volume":"89","author":"Lemp","year":"1973","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2024.11.008_bib19","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","article-title":"Psychometric properties and validation of the standard patient evaluation of eye dryness questionnaire","volume":"32","author":"Ngo","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/ICO.0b013e318191b870","article-title":"The relationship between dry eye symptoms and lipid layer thickness","volume":"28","author":"Blackie","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2024.11.008_bib22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s13555-021-00611-y","article-title":"Urea in dermatology: a review of its emollient, moisturizing, keratolytic, skin barrier enhancing and antimicrobial properties","volume":"11","author":"Piquero-Casals","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jtos.2024.11.008_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2024.11.008_bib24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/ICO.0000000000003418","article-title":"Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study","volume":"43","author":"Protzko","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2024.11.008_bib26","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2024.11.008_bib27","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2147\/OPTH.S442971","article-title":"A randomized, controlled trial comparing Tearcare(\u00ae) and cyclosporine ophthalmic emulsion for the treatment of dry eye disease (SAHARA)","volume":"17","author":"Ayres","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2024.11.008_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2024.11.008_bib29","series-title":"Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25","author":"Kala Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.jtos.2024.11.008_bib30","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/bjo.86.12.1403","article-title":"Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device","volume":"86","author":"Goto","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.11.008_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.eye.6701611","article-title":"Tear film lipid layer thickness and ocular comfort after meibomian therapy via latent heat with a novel device in normal subjects","volume":"19","author":"Mitra","year":"2005","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.jtos.2024.11.008_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.ico.0000208822.70732.25","article-title":"Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction","volume":"25","author":"Matsumoto","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2024.11.008_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtos.2017.01.006","article-title":"Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting","volume":"15","author":"Geerling","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2024.11.008_bib34","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1167\/iovs.14-15764","article-title":"Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction","volume":"56","author":"Craig","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.11.008_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jtos.2020.01.003","article-title":"Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction","volume":"18","author":"Xue","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2024.11.008_bib36","article-title":"Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction","volume":"3","author":"Cote","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtos.2024.11.008_bib37","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s40123-024-00976-1","article-title":"Vectored thermal pulsation as a treatment for meibomian gland dysfunction: a review spanning 15 years","volume":"13","author":"Blackie","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2024.11.008_bib38","series-title":"Comprehensive dermatologic drug therapy","article-title":"51 - therapeutic shampoos","author":"Emerson","year":"2021"},{"key":"10.1016\/j.jtos.2024.11.008_bib39","article-title":"The placebo effect and other confounders","author":"Abelson","year":"2010","journal-title":"Rev Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T08:59:28Z","timestamp":1736758768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012424001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S1542012424001228"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2024.11.008","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2024.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}